PL354998A1 - Podstawione związki oksoazaheterocykliczne - Google Patents

Podstawione związki oksoazaheterocykliczne

Info

Publication number
PL354998A1
PL354998A1 PL00354998A PL35499800A PL354998A1 PL 354998 A1 PL354998 A1 PL 354998A1 PL 00354998 A PL00354998 A PL 00354998A PL 35499800 A PL35499800 A PL 35499800A PL 354998 A1 PL354998 A1 PL 354998A1
Authority
PL
Poland
Prior art keywords
compounds
factor
substituted
oxoazaheterocyclyl compounds
oxoazaheterocyclyl
Prior art date
Application number
PL00354998A
Other languages
English (en)
Inventor
William R. Ewing
Michael R. Becker
Yong Mi Choi-Sledeski
Heinz W. Pauls
Wei He
Stephen M. Condon
Roderick S. Davis
Barbara A. Hanney
Alfred P. Spada
Christopher J. Burns
John Z. Jiang
Aiwen Li
Michael R. Myers
Wan F. Lau
Gregory B. Poli
Original Assignee
Aventis Pharmaceuticals Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Products Inc. filed Critical Aventis Pharmaceuticals Products Inc.
Publication of PL354998A1 publication Critical patent/PL354998A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Dental Preparations (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL00354998A 1999-07-28 2000-07-26 Podstawione związki oksoazaheterocykliczne PL354998A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36319699A 1999-07-28 1999-07-28

Publications (1)

Publication Number Publication Date
PL354998A1 true PL354998A1 (pl) 2004-03-22

Family

ID=23429232

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354998A PL354998A1 (pl) 1999-07-28 2000-07-26 Podstawione związki oksoazaheterocykliczne

Country Status (25)

Country Link
EP (1) EP1208097B1 (pl)
JP (1) JP4829449B2 (pl)
KR (1) KR20020087041A (pl)
CN (1) CN1420882A (pl)
AT (1) ATE423113T1 (pl)
AU (1) AU773227B2 (pl)
BG (1) BG106340A (pl)
BR (1) BR0013179A (pl)
CA (1) CA2382755A1 (pl)
CR (1) CR6563A (pl)
CZ (1) CZ2002323A3 (pl)
DE (1) DE60041584D1 (pl)
EE (1) EE200200045A (pl)
HK (1) HK1054227A1 (pl)
HR (1) HRP20020076A2 (pl)
HU (1) HUP0203375A3 (pl)
IL (2) IL147495A0 (pl)
MX (1) MXPA02000888A (pl)
NO (1) NO20020214L (pl)
PL (1) PL354998A1 (pl)
RU (1) RU2002105011A (pl)
SK (1) SK1182002A3 (pl)
TR (1) TR200200225T2 (pl)
WO (1) WO2001007436A2 (pl)
ZA (1) ZA200200543B (pl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520588A (en) 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
BR0107282A (pt) * 2000-09-29 2004-07-06 Cor Therapeutics Inc Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas
IL157029A0 (en) * 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
ES2258642T3 (es) 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AU2007229363B2 (en) * 2001-08-24 2009-06-04 University Of South Florida Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment
AU2002332640B2 (en) * 2001-08-24 2007-11-08 University Of South Florida Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
EP1502916A4 (en) 2002-04-16 2006-05-31 Teijin Ltd Piperidin derivatives with CCR3-antagonism
JP4429738B2 (ja) 2002-04-25 2010-03-10 帝人株式会社 Ｃｃｒ３拮抗作用を有する４，４−二置換ピペリジン誘導体
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
WO2004032930A1 (ja) * 2002-10-11 2004-04-22 Kowa Co., Ltd. 癌の処置方法
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
AU2004218115A1 (en) 2003-03-07 2004-09-16 Astellas Pharma Inc. Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7393865B2 (en) 2004-06-17 2008-07-01 Neurocrine Biosciences, Inc. Sleep inducing compounds and methods relating thereto
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
ES2528674T3 (es) 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
WO2007008144A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
US20080200431A1 (en) * 2005-07-08 2008-08-21 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CA2653733A1 (en) * 2006-05-26 2007-12-06 University Of Louisville Research Foundation, Inc. Macrophage migration inhibitory factor antagonists and methods of using same
EP1882688A1 (en) 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
PT2364142T (pt) 2008-10-28 2018-04-23 Arena Pharm Inc Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados
US9162987B2 (en) 2009-09-24 2015-10-20 University Of Louisville Research Foundation, Inc. Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions
WO2011146824A1 (en) 2010-05-20 2011-11-24 University Of Louisville Research Foundation, Inc. Methods and compositions for modulating ocular damage
KR101251282B1 (ko) 2010-10-18 2013-04-10 서울대학교산학협력단 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물
CN102532159B (zh) * 2010-11-12 2015-02-11 姚雪彪 动点马达蛋白CENP-E小分子抑制剂Syntelin
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
PL395470A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
DK3137168T3 (da) 2014-04-30 2022-03-21 Univ Columbia Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
RU2712192C2 (ru) 2014-07-31 2020-01-24 Басф Се Способ получения пиразолов
CN104557929B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104592227B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104557927B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104672235B (zh) * 2015-02-14 2016-02-17 佛山市赛维斯医药科技有限公司 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途
CN104610257B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104610259B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104650081B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 凝血因子Xa抑制剂、制备方法及其用途
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN104557930B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂及其用途
CN104557928B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途
CN104650082B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类凝血因子Xa抑制剂、制备方法及其用途
PE20180327A1 (es) 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
US10323027B2 (en) 2015-06-26 2019-06-18 Takeda Pharmaceutical Company Limited 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
US20210147371A1 (en) 2018-04-10 2021-05-20 Bayer Aktiengesellschaft Oxadiazoline derivatives
CN109991355B (zh) * 2019-04-12 2021-05-11 中国烟草总公司郑州烟草研究院 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT71796A (en) * 1993-02-22 1996-02-28 Merck & Co Inc Condensed cyclic compounds with nitrogen heteroatoms and pharmaceutical compositions of fibrinogen receptor antagonistic activity containing them
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
AU747531B2 (en) * 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
WO1999033805A1 (fr) * 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Composes aromatiques presentant des groupements amino cycliques ou leur sels
IL137517A0 (en) * 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
JP2000204081A (ja) * 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
CA2317017A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
JP2003529531A (ja) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤

Also Published As

Publication number Publication date
TR200200225T2 (tr) 2002-06-21
HUP0203375A3 (en) 2005-03-29
CA2382755A1 (en) 2001-02-01
HK1054227A1 (zh) 2003-11-21
CZ2002323A3 (cs) 2002-05-15
WO2001007436A3 (en) 2001-08-23
WO2001007436A2 (en) 2001-02-01
ZA200200543B (en) 2003-08-27
NO20020214D0 (no) 2002-01-15
HUP0203375A2 (hu) 2002-12-28
IL147495A (en) 2007-07-24
SK1182002A3 (en) 2002-11-06
AU6462800A (en) 2001-02-13
BR0013179A (pt) 2002-04-02
MXPA02000888A (es) 2002-07-30
NO20020214L (no) 2002-04-02
ATE423113T1 (de) 2009-03-15
JP2003508353A (ja) 2003-03-04
CN1420882A (zh) 2003-05-28
AU773227B2 (en) 2004-05-20
EP1208097B1 (en) 2009-02-18
IL147495A0 (en) 2002-08-14
DE60041584D1 (de) 2009-04-02
KR20020087041A (ko) 2002-11-21
EP1208097A2 (en) 2002-05-29
RU2002105011A (ru) 2004-01-20
EE200200045A (et) 2003-06-16
HRP20020076A2 (en) 2003-12-31
CR6563A (es) 2008-11-25
BG106340A (en) 2002-10-31
JP4829449B2 (ja) 2011-12-07

Similar Documents

Publication Publication Date Title
IL147495A0 (en) Substituted oxoazaheterocycclyl compounds
YU47600A (sh) SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
DE69830504D1 (de) Antithrombotische mitteln
EP0999834A4 (en) ANTITHROMOSIS
AU2055500A (en) Aromatic amides
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
AU2001280438A1 (en) Substituted heterocyclic amides
DE69931393D1 (de) Antithrombotische amide
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
TWI264437B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
DE60114640D1 (en) Antithrombosemittel
YU76500A (sh) Hemijska sinzeza morfolinskih derivata
MXPA03002493A (es) Proceso eficiente para preparacion de un inhibidor del factor xa.
MY129094A (en) Condensed polycyclic compounds
AU2002339158A1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
AP2001002314A0 (en) Substituted benzolactam compounds.
TR200001161A2 (tr) 8-Siklopentil-6-etil-3-[ikame edilmiş]-5, 8-Dihidro-4H-1, 2, 3A, 7, 8-Pentaaza-As-Indasenlerin hazırlandığı işlem ve burada yararlı ara bağlar.
GR20010100123A (el) Μεθοδος παρασκευης της σιταλοπραμης
AU4865201A (en) An intermediate and process for its synthesis
BG102318A (en) Epoxy-azetidinons, their preparation and application

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)